-
Clinical Trials & Development2 weeks agoAZ and Oracle team up on AI platform for clinical trials
AstraZeneca has launched a project with tech giant Oracle that will use AI and real-world data to improve clinical research and patient care.
-
Capital, M&A & Industry Strategy2 weeks agoRoche offers $15bn for strategic-level deal with Hansoh
A year after signing a first deal with Hansoh worth up to $1.45 billion, Roche has returned for another that could be more than 10 times...
-
Global Biotechnology & Pharmaceutical Markets2 weeks agoUK Biobank partners with industry on ‘most detailed’ immune map
The UK Biobank has teamed up with industry partners to create "the world’s most detailed, large-scale picture of the human immune system."
-
Global Biotechnology & Pharmaceutical Markets2 weeks agoData reveal is promising for GSK’s lung cancer drug ris-rez
The first data from GSK's international trial of B7-H3-targeted ADC ris-rez in small cell lung cancer back up earlier results from a Chinese study.
-
Capital, M&A & Industry Strategy2 weeks agoCancer biotech Nouscom adds €120m, and other financings
A €120m Series D for Swiss biotech Nouscom will support trials of a Lynch syndrome vaccine, with Soufflé, Estuary, and Microbiotica also raising cash.
-
Clinical Trials & Development2 weeks agoNovartis abandons Fabhalta trial in lupus nephritis
A failed phase 2 study has undermined Novartis' hopes of extending the approved indications for Fabhalta to include lupus nephritis.
-
Capital, M&A & Industry Strategy2 weeks agoRNAi biotech City hauls in $200m in upsized IPO
City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference therapies headed by a novel anticoagulant.
-
Regulatory Intelligence & Drug Approvals2 weeks agoCHMP backs Lilly’s oral GLP-1 Foundayo for EU approval
Eli Lilly's oral GLP-1 Foundayo has been recommended for weight reduction and type 2 diabetes in the EU, plus other CHMP decisions.
-
Regulatory Intelligence & Drug Approvals2 weeks agoFDA clears Roche’s Enspryng for thyroid eye disease
Roche has claimed US approval for Enspryng in a second indication, thyroid eye disease, that makes it a rival to drugs from Amgen and Viridian.
-
Regulatory Intelligence & Drug Approvals2 weeks agoRevMed nears EU okay for pancreatic cancer drug Rasonque
Revolution Medicines is just weeks away from getting EU approval for its keenly anticipated oral RAS drug Rasonque for pancreatic cancer.
Widespread atropine use fails to sway FDA advisors on Sydnexis data
At least 11 PDUFAs on FDA’s November docket
FDA Grants Accelerated Approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for Recurrent Respiratory Papillomatosis
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
